Search results for abx831033

Blinatumomab, Abbexa, abx831033

Blinatumomab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD19/CD3E, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto™. Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.